[1]

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394–424.

doi: 10.3322/caac.21492
[2]

Kokudo N, Hasegawa K, Akahane M, Igaki H, Izumi N, Ichida T, et al. Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). Hepatol Res. 2015 Jan;45(2):n/a.
[3]

Kudo M. Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy. Liver Cancer. 2012 Sep;1(2):62–70.

doi: 10.1159/000342402
[4]

Miyaki D, Kawaoka T, Aikata H, Kan H, Fujino H, Fukuhara T, et al. Evaluation of early response to hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma using the combination of response evaluation criteria in solid tumors and tumor markers. J Gastroenterol Hepatol. 2015 Apr;30(4):726–32.

doi: 10.1111/jgh.12821
[5]

Saeki I, Yamasaki T, Tanabe N, Iwamoto T, Matsumoto T, Urata Y, et al. A new therapeutic assessment score for advanced hepatocellular carcinoma patients receiving hepatic arterial infusion chemotherapy. PLoS One. 2015 May;10(5):e0126649.

doi: 10.1371/journal.pone.0126649
[6]

Saeki I, Yamasaki T, Maeda M, Hisanaga T, Iwamoto T, Matsumoto T, et al. Evaluation of the “assessment for continuous treatment with hepatic arterial infusion chemotherapy” scoring system in patients with advanced hepatocellular carcinoma. Hepatol Res. 2018 Feb;48(3):E87–97.
[7]

Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the AsiaPacific region with advanced hepatocellular carcinoma: a phase Ⅲ randomised, double-blind, placebocontrolled trial. Lancet Oncol. 2009 Jan;10(1):25–34.

doi: 10.1016/S1470-2045(08)70285-7
[8]

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228–47.

doi: 10.1016/j.ejca.2008.10.026
[9]

Okuda K, Tanaka M, Shibata J, Ando E, Ogata T, Kinoshita H, et al. Hepatic arterial infusion chemotherapy with continuous low dose administration of cisplatin and 5-fluorouracil for multiple recurrence of hepatocellular carcinoma after surgical treatment. Oncol Rep. 1999 May-Jun;6(3):587–91.
[10]

Ando E, Tanaka M, Yamashita F, Kuromatsu R, Yutani S, Fukumori K, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer. 2002 Aug;95(3):588–95.

doi: 10.1002/cncr.10694
[11]

Kanayama M, Nagai H, Sumino Y. Influence of the etiology of liver cirrhosis on the response to combined intraarterial chemotherapy in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2009 Jun;64(1):109–14.

doi: 10.1007/s00280-008-0851-2
[12]

Ueshima K, Kudo M, Takita M, Nagai T, Tatsumi C, Ueda T, et al. Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma. Oncology. 2010 Jul;78 Suppl 1: 148–53.
[13]

Niizeki T, Sumie S, Torimura T, Kurogi J, Kuromatsu R, Iwamoto H, et al. Serum vascular endothelial growth factor as a predictor of response and survival in patients with advanced hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy. J Gastroenterol. 2012 Jun;47(6):686–95.

doi: 10.1007/s00535-012-0555-6
[14]

Nouso K, Miyahara K, Uchida D, Kuwaki K, Izumi N, Omata M, et al.; Liver Cancer Study Group of Japan. Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan. Br J Cancer. 2013 Oct;109(7):1904–7.

doi: 10.1038/bjc.2013.542
[15]

Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018 Jan;67(1):358–80.

doi: 10.1002/hep.29086
[16]

Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul JL, et al.; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018 Jul;69(1):182–236.

doi: 10.1016/j.jhep.2018.03.019
[17]

Kudo M, Ueshima K, Yokosuka O, Ogasawara S, Obi S, Izumi N, et al.; SILIUS study group. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. Lancet Gastroenterol Hepatol. 2018 Jun;3(6):424–32.

doi: 10.1016/S2468-1253(18)30078-5
[18]

Kishi K, Sonomura T, Mitsuzane K, Nishida N, Kimura M, Satoh M, et al. Time courses of PIVKA-Ⅱ and AFP levels after hepatic artery embolization and hepatic artery infusion against hepatocellular carcinoma: relation between the time course and tumor necrosis. Radiat Med. 1992 Sep-Oct;10(5):189–95.
[19]

Taketa K, Sekiya C, Namiki M, Akamatsu K, Ohta Y, Endo Y, et al. Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions. Gastroenterology. 1990 Aug;99(2):508–18.

doi: 10.1016/0016-5085(90)91034-4
[20]

Sato Y, Nakata K, Kato Y, Shima M, Ishii N, Koji T, et al. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N Engl J Med. 1993 Jun;328(25):1802–6.

doi: 10.1056/NEJM199306243282502
[21]

Yamashita F, Tanaka M, Satomura S, Tanikawa K. Prognostic significance of Lens culinaris agglutinin A-reactive alpha-fetoprotein in small hepatocellular carcinomas. Gastroenterology. 1996 Oct;111(4):996–1001.

doi: 10.1016/S0016-5085(96)70067-7
[22]

Okuda K, Tanaka M, Kanazawa N, Nagashima J, Satomura S, Kinoshita H, et al. Evaluation of curability and prediction of prognosis after surgical treatment for hepatocellular carcinoma by lens culinaris agglutininreactive alpha-fetoprotein. Int J Oncol. 1999 Feb;14(2):265–71.